An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumours, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)

Official Title

Phase 1B Open-Label Study Of The Safety And Clinical Activity Of Crizotinib (PF-02341066) In Tumours With Genetic Events Involving The Anaplastic Lymphoma (ALK) Gene Locus


This is a Phase 1 trial evaluating the safety and efficacy of crizotinib in patients with tumours except non-small cell lung cancer that are positive for ALK.

Trial Description

Primary Outcome:

  • Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs);Type, incidence, severity, seriousness and relationship to study medication of adverse events and any laboratory abnormalities
  • Overall Response Rate
Secondary Outcome:
  • Duration of Response
  • Plasma concentrations of crizotinib
  • Overall Survival
  • Proportion of patients with each of the ALK genetic events
  • Progression-Free Survival (PFS)
  • Phosphorylation status of ALK in the tumour samples from surgery or biopsy pre and post treatment when available

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society